Norihito Tokunaga

This inventor holds 27 USPTO granted patents and 13 published patent applications and 15 EPO patents, primarily in Heterocyclic Compounds. Top assignee: Takeda Pharmaceutical Company Limited. Active years: 2015-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Norihito Tokunaga. Retrieved from https://idiyas.com/inventor/norihito-tokunaga

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 27 (Patent Applications = 13)

% Patents Active = 85.2

EPO Patents = 15 (Patent Applications = 20)

Average Co-Inventor Count = 12.1

ph-index = 5

Forward Citations = 102(Granted Patents)

Location History:

Kanagawa, JP (2015 - 2024)
Fujisawa, JP (2020 - 2024)

Company Filing History:

27 out of 1,226

Takeda Pharmaceutical Company Limited

patents

Years Active: 2015-2026

Loading Chart...

Areas of Expertise:

Heterocyclic Compound

Orexin Receptor Agonists

Pyrrolo[1,2-c]imidazole

Substituted Piperidine

Sulfonamide Derivative

Sleep Disorders

Excessive Sleepiness

Cataplexy

Aromatic Compound

Methods of Use

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12662453 - Heterocyclic compound and use thereof (2026-06-23),

2. 12534471 - Pyrrolo[1, 2-c]imidazole derivatives as orexin type 2 receptor agonists and methods of use thereof (2026-01-27),

3. 12448377 - Heterocyclic compound (2025-10-21),

4. 12421188 - Heterocyclic compound and use thereof (2025-09-23),

5. 12415782 - Heterocyclic compound and use thereof (2025-09-16),

6. 12404237 - Method of treating excessive sleepiness and/or cataplexy using n-{2-(([1,1'-biphenyl]-3-yl)methyl)pyrrolidin-3-yl}sulfonamide derivatives (2025-09-02),

7. 12281073 - Substituted piperidine compound and use thereof (2025-04-21),

8. 12091410 - Heterocyclic compound (2024-09-17),

9. 12077522 - Heterocyclic compound and application thereof (2024-09-03),

10. 12071434 - Heterocyclic compound (2024-08-27),

11. 11987586 - Pyrrolo[1,2-c]imidazole derivatives as orexin type 2 receptor agonists (2024-05-21),

12. 11952344 - Heterocyclic compound and use thereof (2024-04-09),

13. 11713311 - Heterocyclic compound (2023-08-01),

14. 11702419 - Heterocyclic compound and use thereof (2023-07-18),

15. 11655241 - Heterocyclic compound and use thereof (2023-05-23),

Certainly! Here is an article about inventor Norihito Tokunaga:

Title: Unveiling the Inventive Mind of Norihito Tokunaga

Introduction:

In the realm of innovation, there are visionaries who go beyond the ordinary to reshape the future. One such luminary is Norihito Tokunaga. Hailing from Kanagawa, Japan, Tokunaga has solidified his name in the world of patents with a remarkable tally of 16 patents to his credit.

Latest Patents:

1. "Pyrrolo[1,2-c]imidazole derivatives as orexin type 2 receptor agonists": The groundbreaking invention showcases a heterocyclic compound with orexin type 2 receptor agonist activity, offering new possibilities in the realm of narcolepsy treatment.

2. "Heterocyclic compound": Tokunaga's innovative heterocyclic compound with an antagonistic action on an NMDA receptor opens doors for potential therapeutics in major depression, bipolar disorder, and other neurological conditions.

Career Highlights:

Norihito Tokunaga's ingenuity shines brightly at Takeda Pharmaceutical Company Limited, where he melds science and creativity to pave the way for cutting-edge pharmaceutical solutions that can potentially transform lives. His relentless pursuit of excellence has led to numerous breakthroughs in the field of medicinal chemistry.

Collaborations:

In his quest for innovation, Tokunaga collaborates with brilliant minds like Yuichi Kajita and Yuhei Miyanohana, pooling their expertise to push the boundaries of pharmaceutical research and development. Together, they form a formidable team, driving progress and innovation in the ever-evolving landscape of healthcare.

Conclusion:

Inventor Norihito Tokunaga's unwavering dedication to scientific exploration and problem-solving stands as a testament to his unwavering commitment to pioneering advancements that have the power to revolutionize the field of medicine. As he continues to innovate and inspire, the world eagerly anticipates the next chapter in his trailblazing journey of discovery.

Profile summary based on public USPTO records.